How much will patients need to pay out-of-pocket after Besudil is included in medical insurance?

Belumosudil (belumosudil), as a new type of anti-fibrosis targeted drug, has been successfully launched in China and included in the medical insurance catalog, which greatly facilitates patients' access and use. After being included in medical insurance, patients can enjoy the support of the medical insurance reimbursement policy when purchasing Besudil in regular medical institutions, effectively reducing the pressure on treatment costs. However, due to the high price of the drug itself, the actual burden of the patient still needs to be comprehensively considered based on the medical insurance reimbursement ratio and individual circumstances.

Currently, the market retail price of Besudil is about RMB 10,000 to 20,000, which is relatively expensive. Medical insurance reimbursement policies generally vary according to the level of the medical insurance catalog in the patient's region, the payment ratio of the medical insurance pooling fund, and the patient's medical insurance type (such as urban employee medical insurance, urban and rural residents medical insurance). Under normal circumstances, the actual payment by the patient can be reduced from 30% to 70% on the original price. The specific amount needs to be confirmed by the patient's local hospital pharmacy or medical insurance department.

It is worth noting that there is a generic version of Besudil in the overseas market, and the price is significantly lower than the original drug, about 4,000 yuan. This provides patients with a more economical medication option, especially for patients who pay for themselves or patients in areas with insufficient medical insurance coverage. It is an important supplementary channel. However, the quality and efficacy of generic drugs require corresponding regulatory and certification support, and patients should be cautious when choosing them.

Overall, the inclusion of besudil in medical insurance has greatly improved the accessibility of domestic patients. Although the price is higher, the financial burden of patients has been effectively alleviated through medical insurance reimbursement. In the future, with the launch of more generic drugs and the continuous improvement of medical insurance policies, the patient burden of besudil is expected to be further reduced and benefit a wider patient group.

Reference materials:https://www.drugs.com